USFDAAug 7, 2026, 07:07 AM
NRX Pharma's Ketamine ANDA: No Drug-Related Major Deficiencies from FDA
AI Summary
NRx Pharmaceuticals announced that the FDA completed its first-cycle review of the Company's preservative-free ketamine ANDA, identifying no major deficiencies related to the drug product itself, its ingredients, proposed labeling, or Chemistry, Manufacturing and Controls (CMC). The only remaining item is a packaging-related issue concerning manufacturer certification for a luer lock vial, which the FDA classified as a Major Deficiency. NRx is providing the requested attestation, and the FDA has committed to a rapid review, significantly de-risking the path to approval and commercialization. No new clinical, safety, efficacy, or drug-related data are required for approval.
Key Highlights
- FDA completed first-cycle review of NRx Pharmaceuticals' preservative-free ketamine ANDA.
- No major deficiencies identified related to the drug product, ingredients, labeling, or CMC.
- Remaining issue is packaging-related (luer lock vial certification), classified as a Major Deficiency.
- The luer lock vial is used in three FDA-approved ANDA products with 11.9M units shipped without issues.
- NRx will provide manufacturer attestation; FDA committed to the shortest possible review cycle.
- No new clinical, safety, efficacy, or drug-related data are required for ANDA approval.
- NRx believes this outcome substantially de-risks the path to approval and commercialization.
- A conference call and Q&A session is scheduled for August 10, 2026, at 8:30 a.m. ET.
Price Impact
More from NRXP